Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Spinraza Data Review Shows Benefits Of NICE Flexibility

Executive Summary

Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.

You may also be interested in...



Roche To Work On Reversing English Funding Rejection For SMA Drug

Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.

Can The UK Remain A First Launch Market?

More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way

NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel